Company intelligence / Profile preview
Milo Biotechnology
- Ownership
- Private
- Employees
- ~25
- Development stage
- Phase 1
Overview
Milo Biotechnology develops an adeno-associated virus (AAV) gene therapy delivering the follistatin protein to enhance muscle strength and reduce inflammation/fibrosis. Their lead program, AAV1-FS344, has advanced into Phase I/II trials targeting rare neuromuscular diseases such as Becker muscular dystrophy and inclusion body myositis. Early results indicate potential for increased muscle mass and function with a favorable safety profile in these populations.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Gene therapy (AAV-mediated delivery)Protein therapy (follistatin)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Milo Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Milo Biotechnology.